Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Pleural Mesothelioma: Genome-wide Expression Patterns Reflecting General Resistance Mechanisms And A Proposal Of Novel Targets.

O. Røe, E. Anderssen, H. Sandeck, T. Christensen, E. Larsson, S. Lundgren
Published 2010 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma is an asbestos-related multi-resistant tumour with increasing incidence worldwide. Well-characterized snap-frozen normal parietal, visceral pleura and mesothelioma samples were analysed with Affymetrix Human Genome U133 Plus 2.0 GeneChip oligoarray of 38500 genes. We discovered a close relation between gene profile and resistance towards topoisomerase poisons, alkylating agents, antitubulines, antifolates, platinum compounds and radiation therapy. Target genes of chemo- (e.g. TOP2A, BIRC5/Survivin and proteasome) and radiotherapy (e.g. BRCA2, FANCA, FANCD2, CCNB1 and RAD50) were significantly overexpressed. The Fanconi anemia/BRCA2 pathway, responsible for homologous recombination DNA repair appears as a key pathway in both chemo- and radio-resistance of mesothelioma. Leukocyte trans-endothelial migration gene down-regulation could partly explain resistance against immunological therapies. Gene expression features found in other resistant cancer types related to DNA repair and replication are shared by mesothelioma and could represent general features of tumour resistance. Targeted suppression of some of those key genes and pathways combined with chemotherapy or radiation could improve the outcome of mesothelioma therapy. We propose CHEK1, RAD21, FANCD2 and RAN as new co-targets for mesothelioma treatment. The pro-angiogenic AGGF1 mRNA and protein was highly overexpressed in all tumours and may serve as a target for anti-angiogenic treatment. Overexpression of NQO1 may render mesothelioma sensitive to the novel compound beta-Lapachone.
This paper references
10.1016/j.clpt.2006.08.013
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine
M. Oscarson (2006)
10.1073/pnas.0538044100
Selective killing of cancer cells by β-lapachone: Direct checkpoint activation as a strategy against cancer
Y. Li (2003)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.
J. Pink (2000)
10.1038/nature02320
Identification of an angiogenic factor that when mutated causes susceptibility to Klippel–Trenaunay syndrome
Xiao-li Tian (2004)
10.1016/J.CANCERGENCYTO.2006.11.012
Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer.
Y. Yamamoto (2007)
10.1200/JCO.2005.23.16_SUPPL.9651
The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer.
F. Ozdemir (2006)
10.1038/sj.gt.3302595
RNA interference against Hec1 inhibits tumor growth in vivo
E. N. Gurzov (2006)
10.1016/j.mrrev.2007.12.002
Overexpression of DNA repair genes is associated with metastasis: a new hypothesis.
A. Sarasin (2008)
10.1158/0008-5472.CAN-07-1015
Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
C. Jacquemont (2007)
Suppression of RAD 21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells
J. M. Atienza (2005)
Isolation and characterization of a novel human radiosusceptibility gene , NP 95
M Muto (2006)
10.4161/cc.5.11.2796
Genomic Models of Metastatic Cancer: Functional Analysis of Death-from-Cancer Signature Genes Reveals Aneuploid, Anoikis-Resistant, Metastasis-Enabling Phenotype with Altered Cell Cycle Control and Activated PcG Protein Chromatin Silencing Pathway
G. Glinsky (2006)
10.1016/J.JTCVS.2003.08.034
Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma.
Robert J Kruklitis (2004)
10.1242/jcs.000604
Hsp90 is required to localise cyclin B and Msps/ch-TOG to the mitotic spindle in Drosophila and humans
R. Basto (2007)
10.1158/0008-5472.CAN-07-5472
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.
N. Chan (2008)
10.1016/J.YMTHE.2005.12.009
Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus.
Qinglei Gao (2006)
10.1016/J.BREAST.2007.07.021
Using specific cytotoxics with a targeted mind.
A. di Leo (2007)
10.1016/j.bcp.2008.05.019
Uracil in DNA: consequences for carcinogenesis and chemotherapy.
S. Berger (2008)
10.1080/02841860801995396
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D
K. Vang Nielsen (2008)
10.1158/0008-5472.CAN-06-3871
Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway.
M. Pespeni (2007)
10.1200/JCO.1985.3.11.1529
Detorubicin--an active anthracycline in untreated metastatic melanoma.
S. Chawla (1985)
10.1083/JCB1742OIA2
ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability
F. Wegmann (2006)
10.1158/1535-7163.MCT-05-0493
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway
D. Chirnomas (2006)
10.3109/9781420077391-31
Malignant pleural mesothelioma.
Nadgouda Vg (2001)
10.1158/0008-5472.CAN-05-3907
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
Fernando López-Ríos (2006)
10.1074/mcp.R800013-MCP200
A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies*
Lisa Berglund (2008)
10.1016/J.EJCA.2007.08.028
Mesothelin targeted cancer immunotherapy.
R. Hassan (2008)
10.1172/JCI23412
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.
G. Glinsky (2005)
10.2174/157489207780832478
Thalidomide analogues as anticancer drugs.
J. Aragon-Ching (2007)
10.3892/IJMM.19.4.607
Dose-dependent expression changes of early response genes to ionizing radiation in human lymphoblastoid cells.
Xian-Hui Long (2007)
10.1200/JCO.2005.05.4171
DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes.
R. Kennedy (2006)
10.1038/sj.bjc.6604421
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
J. Sørensen (2008)
10.1183/09031936.96.09122565
Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study.
C. J. Lindén (1996)
10.1016/S1470-2045(08)70029-9
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
P. Sève (2008)
10.1038/sj.onc.1209809
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors
A. Borczuk (2007)
10.1002/cncr.23491
Thymidylate synthase in situ protein expression and survival in stage I nonsmall‐cell lung cancer
Zhong Zheng (2008)
Microarray-Based Prognostic Prediction Deletion as Prognostic Factors and Critical Evaluation of P 16 / CDKN 2 A Overexpression of Aurora Kinases and Global Gene Expression Profiling of Pleural Mesotheliomas : Updated
Fernando López-Ríos (2006)
10.1016/J.YEXCR.2006.06.014
The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair.
Kanchan D. Mirchandani (2006)
10.1038/sj.onc.1206946
Resistance to antifolates
R. Zhao (2003)
10.1093/NAR/GKG753
Vanillins--a novel family of DNA-PK inhibitors.
Stephen T. Durant (2003)
10.1158/1078-0432.CCR-07-0536
Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma
A. Sartore-Bianchi (2007)
10.1093/nar/gkm882
KEGG for linking genomes to life and the environment
M. Kanehisa (2008)
The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target.
G. Capalbo (2007)
10.1016/J.FREERADBIOMED.2007.09.022
NF-κB-mediated adaptive resistance to ionizing radiation
K. M. Ahmed (2008)
10.1007/s00428-005-0132-y
Correlation of invasion and metastasis of cancer cells, and expression of the RAD21 gene in oral squamous cell carcinoma
G. Yamamoto (2005)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1074/jbc.M204177200
CARF Is a Novel Protein That Cooperates with Mouse p19 ARF (Human p14 ARF ) in Activating p53*
M. K. Hasan (2002)
10.3109/9781439802014-13
Malignant mesothelioma.
B. Robinson (2005)
10.1093/NAR/GKH872
Repair of U/G and U/A in DNA by UNG2-associated repair complexes takes place predominantly by short-patch repair both in proliferating and growth-arrested cells.
M. Akbari (2004)
10.1667/RR0459.1
Isolation and Characterization of a Novel Human Radiosusceptibility Gene, NP951
M. Muto (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1159/000055914
DNA Topoisomerase II-Alpha Immunoreactivity as a Marker of Tumor Aggressiveness in Invasive Breast Cancer
L. Nakopoulou (2000)
10.1038/ng1352
The Bardet-Biedl protein BBS4 targets cargo to the pericentriolar region and is required for microtubule anchoring and cell cycle progression
J. C. Kim (2004)
10.1016/S0140-6736(05)17947-1
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Y. Wang (2005)
10.1083/JCB.123.4.849
Cytoplasmic dynein plays a role in mammalian mitotic spindle formation
E. Vaisberg (1993)
10.1007/s10637-007-9060-9
In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression
Axel-Rainer Hanauske (2007)
10.1016/S0167-8140(01)00370-X
Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity.
Y. Marcou (2001)
10.1111/j.1349-7006.2008.00741.x
Down regulation of BRCA2 causes radio‐sensitization of human tumor cells in vitro and in vivo
D. Yu (2008)
10.1016/J.BBCAN.2007.10.004
Taxanes, microtubules and chemoresistant breast cancer.
Barbara McGrogan (2008)
Peritoneal mesothelioma: a review.
A. Bridda (2007)
10.1158/1535-7163.MCT-04-0241
Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells
J. M. Atienza (2005)
10.1074/JBC.275.8.5416
NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of β-Lapachone Cytotoxicity*
J. Pink (2000)
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
J. Cusack (2001)
10.1158/1078-0432.CCR-05-1728
Focal Adhesion Kinase Silencing Augments Docetaxel-Mediated Apoptosis in Ovarian Cancer Cells
J. Halder (2005)
Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
H. Beall (1995)
The value of TOP 2 A gene copy number variation as a biomarker in breast cancer : update of DBCG trial 89 D
K VangNielsen (2008)
10.1007/s00066-007-1800-4
The Role of Survivin for Radiation Therapy
G. Capalbo (2007)
10.1111/J.0022-202X.2005.23912.X
Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation.
R. Ludwig (2005)
10.1016/J.LUNGCAN.2005.03.013
Chemotherapy for malignant mesothelioma.
P. Baas (2005)
10.1038/75556
Gene Ontology: tool for the unification of biology
M. Ashburner (2000)
10.1186/1471-2105-8-346
A framework for significance analysis of gene expression data using dimension reduction methods
L. Gidskehaug (2006)
10.1074/JBC.M106287200
S Phase and G2 Arrests Induced by Topoisomerase I Poisons Are Dependent on ATR Kinase Function*
W. Cliby (2002)
10.1074/JBC.M413471200
Mitotic Kinesin Inhibitors Induce Mitotic Arrest and Cell Death in Taxol-resistant and -sensitive Cancer Cells*
A. Marcus (2005)
10.1093/bioinformatics/btf877
Identifying differentially expressed genes using false discovery rate controlling procedures
A. Reiner (2003)
10.2202/1544-6115.1027
Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments
G. Smyth (2004)
10.1016/J.CRITREVONC.2007.02.001
Mechanisms of resistance to cisplatin and carboplatin.
D. Stewart (2007)
10.1038/sj.onc.1210700
High expression of DNA repair pathways is associated with metastasis in melanoma patients
A. Kauffmann (2008)
10.1038/sj.onc.1206935
Mechanisms of resistance to topoisomerase I-targeting drugs
Zeshaan A Rasheed (2003)
10.4161/cc.6367
FERM control of FAK function: Implications for cancer therapy
S. Lim (2008)
10.1016/J.CTRV.2006.09.006
Molecular mechanisms of resistance and toxicity associated with platinating agents.
C. Rabik (2007)
10.1016/J.MRFMMM.2007.09.005
DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair.
D. Spencer (2008)
10.1111/j.1752-699X.2008.00050.x
Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study
G. Hillerdal (2008)
10.1186/1479-7364-1-6-460
Analysis of the glutathione S-transferase (GST) gene family
D. Nebert (2004)
10.1158/0008-5472.CAN-07-5279
Tumor cell dependence on Ran-GTP-directed mitosis.
F. Xia (2008)
Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma.
K. Hassan (2002)
10.1038/ng1061
Identifying distinct classes of bladder carcinoma using microarrays
L. Dyrskjøt (2003)
10.1016/S0014-5793(03)00224-2
The unfolding tale of PECAM‐1
D. Jackson (2003)
10.1111/J.2517-6161.1995.TB02031.X
Controlling the false discovery rate: a practical and powerful approach to multiple testing
Y. Benjamini (1995)
10.1038/sj.onc.1201143
Inactivation of p53 results in high rates of homologous recombination
K. Mekeel (1997)
10.1093/emboj/20.23.6660
Fission yeast Rad50 stimulates sister chromatid recombination and links cohesion with repair
E. Hartsuiker (2001)
10.1016/J.CEB.2006.08.015
The case for survivin as a regulator of microtubule dynamics and cell-death decisions.
D. Altieri (2006)
10.1038/sj.bjc.6604344
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
J. Souglakos (2008)
10.1158/1078-0432.CCR-07-2220
Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention
J. Parsons (2008)
10.1038/sj.bjc.6604208
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
N. Bucher (2008)
10.1007/s00280-007-0539-z
Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed
S. Min (2007)
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Y. Ogiso (2000)
10.1016/J.LUNGCAN.2004.10.005
Thalidomide in patients with malignant pleural mesothelioma.
P. Baas (2005)
10.1007/s00401-006-0180-7
Expression patterns of LIS1, dynein and their interaction partners dynactin, NudE, NudEL and NudC in human gliomas suggest roles in invasion and proliferation
S. Suzuki (2006)



This paper is referenced by
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Nuno Cerveira (2012)
10.1007/s12032-015-0574-2
Overexpression of AGGF1 is correlated with angiogenesis and poor prognosis of hepatocellular carcinoma
W. Wang (2015)
10.1016/j.canlet.2011.08.021
DNA repair systems in malignant mesothelioma.
Dimitrios Toumpanakis (2011)
10.12659/MSM.903248
High Expression of Angiogenic Factor with G-Patch and FHA Domain1 (AGGF1) Predicts Poor Prognosis in Gastric Cancer
Hanhui Yao (2017)
10.1158/0008-5472.CAN-10-3588
Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.
R. Gobble (2011)
10.1186/s12935-019-0765-6
Knockdown of AGGF1 inhibits the invasion and migration of gastric cancer via epithelial–mesenchymal transition through Wnt/β-catenin pathway
Hanhui Yao (2019)
10.1371/journal.pone.0023569
Apoptosis Induced by Piroxicam plus Cisplatin Combined Treatment Is Triggered by p21 in Mesothelioma
A. Baldi (2011)
10.1016/j.ebiom.2018.12.025
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
R. Sciarrillo (2019)
10.1002/jbt.22572
Angiogenic factor with G patch and FHA domains 1 protects retinal vascular endothelial cells under hyperoxia by inhibiting autophagy
Guo-Min Yao (2020)
10.18632/oncotarget.22880
High expression of angiogenic factor AGGF1 is an independent prognostic factor for hepatocellular carcinoma
Jianfei Tu (2017)
10.1016/j.lungcan.2019.10.024
Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.
N. Miyake (2019)
10.1007/978-1-4471-2825-0_19
Malignant Mesothelioma: Molecular Markers
E. Kettunen (2014)
10.1038/bjc.2013.731
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma
A. Linton (2014)
10.1002/ijc.25763
ERK2 is essential for the growth of human epithelioid malignant mesotheliomas
A. Shukla (2011)
10.1371/journal.pone.0006554
Genome-Wide Profile of Pleural Mesothelioma versus Parietal and Visceral Pleura: The Emerging Gene Portrait of the Mesothelioma Phenotype
O. D. Røe (2009)
10.3390/ijms21176342
Genomics and Functional Genomics of Malignant Pleural Mesothelioma
Ece Çakıroğlu (2020)
10.1186/s12885-019-5314-0
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
Sabrina Borchert (2019)
10.1007/978-1-4899-8032-8_15
Ran GTPase in nuclear envelope formation and cancer metastasis.
K. Matchett (2014)
10.1158/1078-0432.CCR-10-2873
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin
P. A. Zucali (2011)
10.1038/bjc.2013.731
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma
A. Linton (2014)
Novel functions for the BAF180 tumour suppressor : insights from mammalian and yeast systems
P. M. Brownlee (2014)
10.1016/j.kjms.2015.10.002
Identification of genes associated with melanoma metastasis
T. Qiu (2015)
10.1371/journal.pone.0040521
Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma
O. D. Røe (2012)
10.1016/j.canlet.2016.03.020
(64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.
Yukie Yoshii (2016)
10.5858/arpa.2011-0215-RA
Molecular changes in mesothelioma with an impact on prognosis and treatment.
D. Jean (2012)
10.1111/j.1349-7006.2009.01336.x
Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells
Y. Sekido (2010)
Exosomes And Their Role In Asbestos Exposure And Mesothelioma
Phillip B. Munson (2019)
10.1016/j.mrrev.2011.12.003
A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.
O. Melaiu (2012)
10.1096/fj.201701291RR
Exosomes from asbestos‐exposed cells modulate gene expression in mesothelial cells
Phillip B. Munson (2018)
Treated with Pemetrexed / Carboplatin PatientsGroup-1 as Predictors of Responsiveness in Mesothelioma Thymidylate Synthase and Excision Repair Cross-Complementing
Paolo Andrea Zucali (2011)
10.1016/j.mrfmmm.2014.11.002
Expression status of candidate genes in mesothelioma tissues and cell lines.
O. Melaiu (2015)
10.4267/2042/44843
RAN (RAN, member RAS oncogene family)
Wilhelmina Maria Rensen (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar